Heat Biologics, Inc. Banner Image

Heat Biologics, Inc. has reached its limit for free report views

Work for Heat Biologics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Heat Biologics, Inc.

  • Ticker HTBX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Heat Biologics, Inc. Logo Image
  • 11-50 Employees
  • Based in Durham, North Carolina
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trialMore, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.
4.8 / 5.0 (240)

Heat Biologics, Inc. reports have an aggregate usefulness score of 4.8 based on 240 reviews.

Heat Biologics, Inc.

Most Recent Annual Report

Heat Biologics, Inc.
MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Heat Biologics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports

Heat Biologics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!